tiprankstipranks
Trending News
More News >

Estrella Immunopharma announces additional site for STARLIGHT-1 trial

Estrella Immunopharma (ESLA) announced the activation of a second clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected Artemis T-cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma. The new site, Baylor Research Institute d/b/a Baylor Scott & White Research Institute in Dallas, Texas, is now open for patient enrollment.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1